The Royal United Hospitals (RUH) Bath NHS Foundation Trust is actively recruiting volunteers for a pivotal clinical trial investigating a new anticoagulant drug aimed at reducing the risk of recurrent strokes.
This innovative study, known as Librexia, is set to evaluate the efficacy of Milvexian, a groundbreaking medication designed to lower the chances of future ischaemic strokes in patients with a history of stroke or transient ischaemic attack (TIA).
Individuals aged 40 and above who have visited the RUH within 48 hours following an ischaemic stroke or TIA are encouraged to participate in this vital research.
Volunteers will play a crucial role in determining whether Milvexian can effectively prevent additional strokes, ultimately contributing to improved outcomes for stroke survivors.
Ischaemic strokes occur when a blockage interrupts blood flow to a specific region of the brain, leading to cell death and potential long-term disabilities such as speech and visual impairments, along with numbness or weakness in limbs.
Conversely, a transient ischaemic attack is caused by a temporary disruption of blood flow to the brain, resulting in sudden, stroke-like symptoms that resolve quickly but indicate a significant risk for future strokes.
Milvexian works by thinning the blood to help prevent the formation of dangerous blood clots within the bloodstream. Participants in the Librexia study will be randomly assigned to receive either Milvexian or a placebo, in conjunction with standard medications as prescribed by their healthcare providers.
Regular follow-up appointments will be held at RUH every 13 weeks for assessments, includingg comprehensive blood tests and evaluations of liver and kidney function.
Kelly Spencer, head of research operations at RUH, expressed enthusiasm about the hospital’s involvement in this significant study, underscoring the importance of advancing medical research in stroke prevention.
“The RUH is well-respected for its commitment to research and studies like these reflect our ongoing work to support vital medical trials which can help us better care for our patients now and in the future,” she said.
